Why IMU is a multi multi bagger, page-17488

Thx PDS,

I saw the Cap Raise over at CHM but I didn’t know Steini spat the dummy!

That’s terrible luck, holding enough shares to get on the BOD, and getting slammed with a second SPP. With that many shares it is a lot of cash to find in these times..

Question is, with such an early stage biotech , would one expect more capital to be needed.

What I don’t understand is why Steini would have so much exposure to Gioblastoma Cancer. Congratulations to CHM for being the first CarT to hit a solid tumor and first drug to hit a Gioblastoma, but the Vaxinia MAST trial in also enrolling patients with the same tumors.

If Vaxinia is shown to kill all cancers and shrink Gioblastoma why would an investor choose the be heavily exposed to both companies?

Maybe I’m missing something here, but it seems illogical. I realise plenty of posters hold both companies. IMU might release news in just over a weeks time at the SITC conference that shows CF33/Vaxinia is doing the same thing to Gioblastoma.

Which company would you hold then?